AI Article Synopsis
Article Abstract
Background And Objective: In end-stage kidney disease, high urea levels promote the carbamylation of lysine side chains on a variety of proteins, including albumin. Albumin carbamylation has been identified as a risk factor for mortality and sevelamer led to a decrease in urea levels in dialysis patients. In the present secondary analysis of the NICOREN trial, we investigated the putative impacts of sevelamer and nicotinamide on albumin carbamylation, and the potential correlation between carbamylation and vascular calcifications.
Methods: All possible carbamylation of circulating albumin were screened for with high-resolution liquid chromatography-tandem mass spectrometry. Levels of three carbamylated peptides were then measured as a guide to the extent of albumin carbamylation. Carbamylation was measured at baseline in 55 patients included in the NICOREN trial and 29 patients at 24 weeks of treatment. Calcifications on plain radiographs were quantified as the Kauppila score and the Adragao score.
Results: Baseline albumin carbamylation was present at three different sites in subjects with end-stage kidney disease. At baseline, we observed only a correlation between urea and the KQTA carbamylation site in these patients. Albumin carbamylation levels did not decrease after 24 weeks of treatment with either sevelamer or nicotinamide. Furthermore, the proportion of carbamylated serum albumin was not correlated with vascular calcification scores in this population.
Conclusions: Our results confirmed the presence of carbamylated albumin in patients with end-stage kidney disease and demonstrated the presence of carbamylation beyond the LRVP residues. The results also demonstrated the lack of impact of sevelamer or nicotinamide on albumin carbamylation levels. Therapeutic strategies to lower carbamylation load should probably be focused on direct anti-carbamylation processes and/or potentially anti-inflammatory therapies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8206311 | PMC |
| http://dx.doi.org/10.1007/s40268-021-00350-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Introduction: The processes of atherosclerosis, inflammation, and carbamylation are closely linked in cardiovascular (CV) disease, but the potential of carbamylation burden as a CV mortality predictor is unclear, especially in patients with no or mild chronic kidney disease (CKD). This study aimed to investigate whether elevated carbamylated albumin (C-Alb), as a surrogate marker for carbamylation burden, is associated with mortality and arterial stiffness/atherosclerotic burden in patients with no or mild CKD, using pulse pressure (PP) as a marker for arterial stiffness.
Methods: We measured C-Alb in 3,193 participants of the Ludwigshafen Risk and Cardiovascular Health study who had been referred for coronary angiography and followed up for 10 years.
Comparative CKD risk prediction using homocitrulline and carbamylated albumin: two circulating markers of protein carbamylation.
BMC Nephrol
May 2024
Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Article Synopsis
- Protein carbamylation, influenced mainly by urea, has a negative impact on clinical outcomes for patients with chronic kidney disease (CKD), with key biomarkers being carbamylated albumin (C-Alb) and homocitrulline (HCit).
- In a study involving 1,632 CKD participants, both C-Alb and HCit were measured together to assess their prognostic value for death and end-stage kidney disease (ESKD).
- The findings showed that both biomarkers were significantly associated with increased risks for death and ESKD, and they had comparable prognostic capabilities in statistical models.
Distribution and clinical significance of anti-carbamylation protein antibodies in rheumatological diseases among the Chinese Han population.
Front Immunol
August 2023
Department of Rheumatology and Immunology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Objective: Several studies have demonstrated that anti-carbamylation protein antibodies (Anti-CarPA) are persistent in patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), systemic sclerosis (SSC), primary Sjögren's syndrome (pSS), and interstitial lung disease associated with RA (RA-ILD). However, the relationship between anti-CarPA and other rheumatic diseases (RDs) and non-RA-ILD is not known till now. This study sought to examine the presence of anti-CarPA in Chinese Han patients with RDs and its clinical significance.
View Article and Find Full Text PDFComparison of homocitrulline and carbamylated albumin as biomarkers of carbamylation reactions in hemodialyzed patients.
Amino Acids
October 2023
Division of Nephrology, Ambroise Paré Hospital and Paris Ile de France Ouest University, 9 Avenue Charles de Gaulle, 92104, Boulogne Billancourt Cedex, France.
Article Synopsis
- - The study examined the link between homocitrulline (HCit) levels and albumin carbamylation in hemodialyzed patients participating in the NICOREN trial, using specialized testing methods.
- - Results revealed that HCit concentrations were significantly correlated with the degree of albumin carbamylation, showing that higher HCit levels indicate more carbamylation in patients.
- - Importantly, neither sevelamer nor nicotinamide treatments reduced HCit or carbamylated albumin levels after 24 weeks, suggesting that HCit could serve as a useful biomarker for protein carbamylation in clinical settings.
Posttranslational-modifications of human-serum-albumin analysis by a top-down approach validated by a comprehensive bottom-up analysis.
J Chromatogr B Analyt Technol Biomed Life Sci
May 2023
P&T, UMR1248, University of Limoges, National Institute for Health and Medical Research (INSERM), Limoges, France; Department of pharmacology, toxicology and pharmacovigilance, CHU Limoges, Limoges, France. Electronic address:
The posttranslational modifications (PTM) of human serum albumin (HSA) can result in the development of isoforms that have been identified as potential biomarkers for advanced hepatic diseases. However, previous approaches using top-down (TD) analysis to identify isoforms based on molecular weight may have resulted in misidentifications. The nature of the identified isoforms has never been confirmed in previous works.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!